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It is now well established that human tumors express
unique antigens, however tumor immune evasion
mechanisms often prevent effective naturally occurring
anti-tumor immune responses. We hypothesized that
infusion of T cells that have been genetically modified
to express affinity-optimized antigen-specific TCRs may
help overcome these barriers. We initiated a study to
evaluate the antitumor efficacy of T cells engineered
with an affinity-enhanced TCR specific for the NY-ESO-
1 and LAGE-1 cancer testis antigens (NY-ESOc259-T) in
multiple myeloma (MM) patients with antigen-positive
tumors in the setting of an autologous stem cell trans-
plant (NCT01352286). Clinical outcomes of this study
have been previously published; clinical data demon-
strated safety and encouraging rates of clinical responses,
although durability could be further improved. Therefore,
in order to better understand the correlates of response,
resistance, and relapse, we initiated a deep characteriza-
tion of the engineered T cell and tumor phenotype in
clinical study participants, and we report the initial find-
ings from these studies here.
To better understand the immune profile of the T cell
product and its fate post infusion, baseline and post infu-
sion PBMCs were analyzed by flow cytometry evaluating
memory and exhaustion markers (e.g. CD45RA, CCR7,
PD-1) and polyfunctionality/cytotoxicity markers (e.g.
IFN-g and Granzyme B). NY-ESOc259-T cells were
detected by pentamer staining and their phenotype was
correlated with clinical response. Hierarchical cluster ana-
lysis was applied to identify trends of expression of surface
markers in different patient subsets. Analysis of cytokine
production and polyfunctionality reveal how polyfunc-
tional CD8+ and CD4+ NY-ESOc259-T cells evolve upon
infusion and selectively regulate different cytokines, with
patients displaying different degrees of polyfunctionality.
Analysis of baseline T cell profile in patients against the
final manufactured product revealed an interesting evolu-
tion in markers expression, with CD8+ cells acquiring the
most diverse phenotype, and CD4+ cells retaining a more
central memory phenotype.
Some patients relapsed despite a low level presence of
NY-ESOc259 T in marrow. To better understand the
mechanisms through which tumor cells evade T cell–
mediated destruction, we evaluated the surface expression
of over 330 proteins on myeloma cells from bone marrow
samples using a flow cytometry-based array. The results
revealed the upregulation of several immunosuppressive
markers, including PDL-1, on myeloma cells associated
with poor prognosis and trafficking, as well as immuno-
suppression following T cell infusion. This analysis is cur-
rently being extended to include additional time points
allowing changes in these markers to be tracked before
and after therapy and, where applicable, at points of
relapse.
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